Clinical trials: Plasma Cells
Bioequivalence
A Pilot Bioequivalence Study of Pomalidomide
Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.
- Trial name
- NCT03424928
- Testing
- Pomalidomide 4 MG Oral Capsule, Pomalidomide 4 MG Oral Capsule-Pomalyst
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Colo-rectal Cancer
Plasma-based Colorectal Cancer Screening Research & Development
The objective of this Clinical Sample Collection Study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e.
- Trial name
- NCT04027790
- Testing
- Epi proColon
- Where
- 5 sites in United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Amyloidosis
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GSK3039294 has been developed in order to offer an orally available alternative to parenteral CPHPC (GSK2315698 [metabolite of GSK3039294]) for plasma serum amyloid P component (SAP) depletion prior to use of anti SAP monoclonal…
- Trial name
- NCT02603172
- Testing
- GSK3039294
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
- Trial name
- NCT01089998
- Testing
- BAY86-9596, Fludeoxyglucose (18F)-IBA
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4.
- Trial name
- NCT02998047
- Testing
- Lintuzumab AC 225
- Where
- 5 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Actinium Pharmaceuticals
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Blood Donors
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
This study will evaluate a new blood collection and filtration system that is intended to be used to collect, filter, separate and store red blood cells and, separately, plasma.
- Trial name
- NCT02145507
- Testing
- SOLX (Investigational), AS-3 (Control)
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
22q.11.2 Deletion/Duplication
Non-Invasive Chromosomal Evaluation of 22q11.2
This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.
- Trial name
- 22Q (NCT02541058)
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Cindy Cisneros
Hair Disease
AGA Biocellular Stem/Stromal Hair Regenerative Study
Purpose The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma…
- Trial name
- STRAAND (NCT02849470)
- Testing
- Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Healeon Medical Inc
Neural Tube Defects, Contraception
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
The purpose of this study is to determine whether the study drug is safe and effective
- Conditions
- Neural Tube Defects, Contraception, Oral Contraceptives (OC)
- Trial name
- NCT00468481
- Testing
- Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
- Where
- 9 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants, Breast Cancer
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
This study aims to evaluate the feasibility of using See.d instrument and SBS slides for preparation of plasma and cytological samples from whole blood.
- Trial name
- NCT06097156
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Plasma Cell Myeloma
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended…
- Trial name
- NCT04000282
- Testing
- SAR442085
- Where
- 12 sites in United States, Czechia and 4 more
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival
Feasibility trial to evaluate recovery and survival of red blood cells (RBCs) from Mirasol-treated whole blood
- Trial name
- IMPROVE (NCT00742001)
- Testing
- Mirasol System for Whole Blood.
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Terumo BCTbio
Multiple Myeloma
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects
- Trial name
- NCT05679258
- Testing
- HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX®
- Where
- 2 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Contraception
Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate
The purpose of this study is to examine and compare the uptake of levomefolate calcium (Metafolin, a registered vitamin supplement) and folic acid in the body during 24 weeks of treatment with a following folate elimination phase…
- Trial name
- NCT01258660
- Testing
- EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid
- Where
- Germany
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Bayer
Leiomyoma, Uterine, Leiomyosarcoma Uterus
Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy
The development of precise and non-invasive diagnostic methods is a priority in areas such as gynaecology and oncology, and above all in improving the health of those patients with a surgical indication for hysterectomy…
- Trial name
- MYOSARCII (NCT04935333)
- Testing
- Collection of Leiomyoma samples, Collection of Leiomyosarcoma samples, Collection of control samples
- Where
- 21 sites in Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Igenomix
Plasma Cell Leukemia, Multiple Myeloma
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage therapy for Multiple Myeloma (MM). The present study is designed to assessment the efficacy and safety study of Bortezomib in combination…
- Trial name
- Bortezomib (NCT01328236)
- Testing
- Bortezomib, Liposome doxorubicin, Dexamethasone
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Clinical Service, China
Multiple Myeloma
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male…
- Trial name
- NCT07400744
- Testing
- QL2109, Darzalex
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy Participants
Feasibility Study Aiming at Pre-Analytical Standardization of Whole Blood Processing for Liquid Biopsy Applications
The goal of this feasibility study is to evaluate a new sample preparator called See.d. After blood processing the instrument will produce a set of slides and a tube of plasma.
- Trial name
- NCT05942066
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.